Peptide research profile
Mazdutide: GLP-1/glucagon dual agonism and the clinical evidence
Mazdutide, also known as IBI362, is a dual GLP-1 and glucagon receptor agonist developed through a clinical program in China. Early and mid-stage randomized evidence is informative, while comparisons with other incretin programs remain indirect unless tested head to head.
Educational content only. Not medical advice.
A different dual-agonist pairing
Mazdutide is a peptide-based agonist designed to engage GLP-1 and glucagon receptors. That receptor pair differs from tirzepatide's GIP and GLP-1 profile and from retatrutide's triple profile. The intended biology combines GLP-1-related metabolic signaling with glucagon-receptor activity, but observed outcomes must come from clinical trials, not pathway diagrams.
The development code IBI362 appears in parts of the literature. Searching both names is important for a complete evidence map and for avoiding the mistaken impression that they are separate programs.
What phase 1b contributed
A randomized phase 1b study in Chinese participants with overweight or obesity evaluated multiple mazdutide groups over a relatively short period. Early-stage studies can characterize pharmacology, tolerability, and preliminary outcome signals, but their size and duration limit conclusions about durability and uncommon harms.
The phase 1b report is useful as a bridge from mechanism to later testing. It should not be treated as definitive effectiveness evidence or generalized beyond its studied population and design.
What the randomized phase 2 report adds
A larger randomized, double-blind, placebo-controlled phase 2 trial evaluated mazdutide in Chinese adults with overweight or obesity. It reported group-level changes in body weight and cardiometabolic measures and documented adverse events across the study period.
Phase 2 results help select later-stage questions and provide controlled human evidence. They do not by themselves establish superiority to semaglutide, tirzepatide, or retatrutide because the trials differ in population, duration, receptor profile, comparator, and analysis.
Development and comparison limits
Mazdutide's regulatory and development status is jurisdiction- and date-specific. Official national regulator records and current trial registries should be consulted before describing authorization. A press release is not a replacement for a regulator decision or peer-reviewed results.
This profile contains no dose, titration, administration, procurement, or reconstitution material. Its purpose is to connect a defined molecule to its published study program and remaining questions.
Evidence limits
- The highlighted trials were conducted in defined Chinese populations, which limits unqualified generalization.
- Cross-trial comparisons with other incretin agonists cannot establish superiority.
- Regulatory and later-stage development status require a current jurisdiction-specific official check.
Sources and further reading
These sources ground the definitions and evidence boundaries on this page. A citation is a route for verification, not an endorsement of a product or personal use.
Nature Communications
Efficacy and safety of mazdutide in Chinese adults with overweight or obesity
Open-access primary randomized phase 2 report supporting the population, outcomes, and safety context.
Open sourceEClinicalMedicine
Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) in Chinese adults with overweight or obesity
Open-access early human study supporting development history and the limits of short, early-stage evidence.
Open sourceU.S. National Library of Medicine
ClinicalTrials.gov Glossary Terms
Official definitions used to distinguish phases, statuses, outcomes, and study records.
Open sourceCommon questions
Is mazdutide the same receptor combination as tirzepatide?
No. Mazdutide targets GLP-1 and glucagon receptors; tirzepatide targets GIP and GLP-1 receptors.
Do phase 2 results prove mazdutide is better than another agonist?
No. They provide controlled evidence against that trial's comparator. Reliable superiority claims require direct comparative evidence or a carefully justified synthesis.
Continue with context
Continue in the PeptideSchool workspace
Use the member workspace to organize references, compare research notes, and explore the complete peptide library. Protocol, dosage, and reconstitution material remains inside the appropriate Premium context.